

### MAJEDIE INVESTMENTS PLC

UK INVESTOR MAGAZINE PRESENTATION NOVEMBER 2025

### IMPORTANT REGULATORY INFORMATION

This document has been approved and issued by Marylebone Partners LLP ("Marylebone") as a financial promotion for distribution in the United Kingdom. Marylebone Partners LLP is authorised and regulated by the Financial Conduct Authority of the United Kingdom (the "FCA") (Reference Number: 596118). It is registered in England and Wales (Company Number OC381480) and has its registered office at: 1 Giltspur Street, Farringdon, London, EC1A 9DD.

Marylebone is the alternative investment fund manager of Majedie Investments PLC ("the Company), a UK listed investment trust. The Company is registered in England and Wales (Company Number 109305) and has its registered office at: Dashwood House, Old Broad Street, London, EC2M 1QS, United Kingdom.

This document is intended to be of general interest only and does not constitute legal, regulatory, tax, accounting, investment or other advice nor is it an offer to buy or sell shares in the Company (or any other investment mentioned herein). Nothing in this document should be construed as a personal recommendation to invest in the Company (or any other investment mentioned herein) and no assessment has been made as to the suitability of such investments for any investor. In making a decision to invest, prospective investors may not rely on the information in this document.

Such information is subject to change and does not constitute all the information necessary to adequately evaluate the consequences of investing in the Company.

Investors should not subscribe for any shares in the Company on the basis of the information in this document. Investors should refer to the information contained within the Company's Key Information Document ("KID") and the latest Annual or Half-Yearly Financial Reports before making any decision to invest. Investors should also seek independent professional advice before making any decision to invest in the Company.

Capital at risk. The value of shares in the Company (and any income derived from them) can go down as well as up and you may not get back the amount that you have invested.

The shares in the Company are listed on the London Stock Exchange. Their price is affected by supply and demand and is therefore not necessarily the same as the value of the underlying assets. Changes in currency rates of exchange may have an adverse effect on the value of the Company's shares (and any income derived from them). Any change in the tax status of the Company could affect the value of the Company's shares or its ability to provide returns to its investors. Levels and bases of taxation are subject to change and will depend on your personal circumstances. The Company can borrow money to make investments (known as 'gearing'), which can enhance returns in a rising market but will magnify losses if the value of the Company's investments falls. You should consult your own professional advisers on the tax implications of making an investment in, holding or disposing of any of the Company's shares, and on the receipt of dividends.

Past performance is not a reliable indicator of future returns. Any return estimates or indications of past performance cited in this document are for information purposes only and can in no way be construed as a guarantee of future performance. No representation or warranty is given as to the performance of the Company's shares and there is no guarantee that the Company will achieve its investment objective.


For more information on the Company, and the risks associated with an investment in the Company's shares, please refer to the Company's Key Information Document (KID) and the latest Annual or Half-Yearly Financial Reports, copies of which are available at: <a href="https://www.majedieinvestments.com/">https://www.majedieinvestments.com/</a>.

Marylebone has taken all reasonable care to ensure that the information contained in this document is accurate at the time of publication, however it does not make any guarantee as to the accuracy of the information provided. Marylebone has no obligation to provide further information, to update the information or correct any inaccuracies identified. While many of the thoughts expressed in this document are presented in a factual manner, the discussion reflects only Marylebone's beliefs and opinions about the financial markets in which it invests portfolio assets following its investment strategies, and these beliefs and opinions are subject to change at any time. Where information provided in this document contains "forward-looking" information including estimates, projections and subjective judgment and analysis, no representation is made as to the accuracy of such estimates or projections or that such projections will be realised. Comparison to an index, where shown, is for information only and should not be interpreted to mean that there is a correlation between the portfolio and the index.

To the fullest extent permitted by law, neither Marylebone nor the Company shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document. Should you undertake any investment or activity based on information contained in this document, you do so entirely at your own risk.

### MARYLEBONE PARTNERS' LIQUID-ENDOWMENT MODEL

- Long-term, fundamental mind set.
- With equities at its heart, we harness idiosyncratic return sources for Majedie.
- Majedie does not allocate to illiquid strategies or low-return asset classes.
- Every investment in the Majedie portfolio is marked-to-market frequently.



### COMPLEMENTARY, FUNDAMENTAL, DIFFERENTIATED

### **EXTERNAL MANAGERS**

Fundamental investors
Boutique firms, investment led
Domain expertise in niche areas
Capacity constrained, hard to access



### SPECIAL INVESTMENTS

Co-invests, thematic opportunities, SPVs

High return potential Trusted Source <3 years time horizon

### **DIRECT INVESTMENTS**

8-12 developed-market public equities


Quality + Growth Unappreciated Change

Returns are not guaranteed.

### SINCE OUR APPOINTMENT

### NAV TOTAL RETURN ANNUALISED AT +9.9%, SHARE PRICE TOTAL RETURN ANNUALISED AT +14.2%

### **Share Price & Net Asset Value (total return)**



Source: Majedie Investments PLC. As of 30 September 2025. Past performance is not an indicator of future returns. Debenture repaid at end of March 2025.


### THE INVESTMENT LANDSCAPE HAS CHANGED

### IT'S ABNORMAL, NO LONGER...

### OLD REGIME

- Falling interest rates lifted markets and suppressed dispersion.
- Broad exposure to equities generated strong absolute returns.
- US assets outperformed everything else.
- Indices became concentrated in a few mega-cap growth stocks.

### A generational repositioning?




Source: Board of Governors of the Federal Reserve System (US). As of March 2025

### NEW REGIME

- Higher interest rates, less leverage and variable liquidity.
- · Fewer market tailwinds to deliver absolute returns.
- Performance differentials should widen.
- Security selection will be paramount.


### Fundamentally-driven dispersion




Source: Bloomberg, Goldman Sachs Global Investment Research


### **#1 OPPORTUNITIES IN ASIA**

### China: unleashing household savings



### Japan: Unlocking corporate cash hoards






Source: Longview Economics, Macrobond


Source: Japan Life Insurance Association

### #2 BOTTOM-UP STOCK PICKS CLOSER TO HOME

### Weir Group plc: operational leverage



### Computacenter plc: undervalued growth



Source: Weir Group plc, Marylebone Partners


Source: Computacenter plc, Interim Report 2025

### #3 'DISPROVING NEGATIVES' IN THE UNITED STATES

### Clinical-stage biotech: Trump slump

# 10 0 -10 -10 -10 -10 -20 Commercial-Stage Clinical-Stage Clinical-Stage Commercial-Stage Commercial-Stage

### Software stocks: left behind in the AI frenzy




Source: Morgan Stanley, Bloomberg Source: S&P Capital IQ

### #4 REAL ASSETS SUPPORTED BY FUNDAMENTALS NOT SENTIMENT

### Electrification adds to copper demand story

## Mt copper demand 60 40 20 2021 Economic growth transition Data centres Substitution / 2050 thrifting


### Nuclear fuel buyers face a uranium supply deficit




Source: BHP analysis Source: Kazatomprom

### **#5 SPECIAL INVESTMENTS**

### CVS Health: a deep-value turnaround story



### Orizon VdeR: value creation beyond landfills



Source: CVS Health Corporation

Source: Hix Capital, Orizon Valorização de Resíduos S.A

### THE PORTFOLIO

### TOP 5 HOLDINGS BY STRATEGY

### **EXTERNAL MANAGERS**

63%

### **DIRECT INVESTMENTS**

17%

### SPECIAL INVESTMENTS

16%

**CASH** 

4%

Contrarian Emerging Markets
Perseverance DXF Value
Helikon L/S Equity
Silver Point Capital Partners
Millstreet Credit

Global X Copper Miners ETF

Computacenter plc

Weir Group plc

IMI plc

Cancom SE

Uranium

Bank of Cyprus

Orizon

Oxford Biomedica plc

CVS Health Corp



Source: Majedie Investments PLC. Shows top 5 positions in each strategy, as of 30 September 2025. Map shown is for illustrative purposes only.

### CONCLUDING THOUGHTS

### POSITIONED TO PERFORM

- High-conviction, non-consensual opportunities > differentiated absolute returns.
- Modest expectations + improving fundamentals = margin of safety.
- Overlooked equities, specialist credit, and real assets with structural imbalances.
- A sterling asset: FX moves will not determine success.
- A marked-to-market, equity-centric portfolio.
- Fully invested stance reflects our perception of risk-adjusted return potential.

Returns are not guaranteed.

### MARYLEBONE PARTNERS LLP

Differentiated fundamental investments